Analysis of 30 patients with persistent or recurrent squamous cell carcinoma of the cervix within one year after concurrent chemoradiotherapy

References

1. 1.↵
   2. Eifel PJ,
   3. Winter K,
   4. Morris M,
   5. Levenback C,
   6. Grigsby PW,
   7. Cooper J, et al.

   Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervicalcancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 2004;22:872–880.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   2. Hong JH,
   3. Tsai CS,
   4. Lai CH,
   5. Chang TC,
   6. Wang CC,
   7. Chou HH, et al.

   Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004;60:249–257.

   OpenUrlCrossRefPubMedWeb of Science
3. 3.↵
   2. Eifel PJ,
   3. Jhingran A,
   4. Brown J,
   5. Levenback C,
   6. Thames H.

   Time course and outcome of central recurrence after radiation therapy for carcinoma of the cervix. Int J Gynecol Cancer 2006;16:1106–1111.

   OpenUrlAbstract/FREE Full Text
4. 4.
   2. Moore DH,
   3. Tian C,
   4. Monk BJ,
   5. Long HJ,
   6. Omura GA,
   7. Bloss JD.

   Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2010;116:44–49.

   OpenUrlCrossRefPubMed
5. 5.↵
   2. Zanetta G,
   3. Torri W,
   4. Bocciolone L,
   5. Lucchini V,
   6. Mangioni C.

   Factors predicting response to chemotherapy and survival in patients with metastatic or recurrent squamous cell cervical carcinoma: a multivariate analysis. Gynecol Oncol 1995;58:58–63.

   OpenUrlCrossRefPubMed
6. 6.↵
   2. Hirakawa M,
   3. Nagai Y,
   4. Inamine M,
   5. Kamiyama K,
   6. Ogawa K,
   7. Toita T, et al.

   Predictive factor of distant recurrence in locally advanced squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy. Gynecol Oncol 2008;108:126–129.

   OpenUrlCrossRefPubMed
7. 7.↵
   2. Zhang M,
   3. Cai S,
   4. Wang X.

   Analysis of patients with persistent cervical cancer after radiotherapy. Zhonghua Fu Chan Ke Za Zhi 1999;34:692–693.

   OpenUrl
8. 8.↵
   2. Yu L,
   3. Lou G,
   4. Zhang Y.

   Analysis of factors related with local failure of advanced cervical cancer after concurrent chemoradiotherapy. Shiyong Fu Chan Ke Za Zhi 2006;22:359–361.

   OpenUrl
9. 9.↵
   2. Song S,
   3. Rudra S,
   4. Hasselle MD,
   5. Dorn PL,
   6. Mell LK,
   7. Mundt AJ, et al.

   The effect of treatment time in locally advanced cervical cancer in the era of concurrent chemoradiotherapy. Cancer 2013;119:325–331.

   OpenUrlPubMed
10. 10.↵
    2. Huang EY,
    3. Huang YJ,
    4. Chanchien CC,
    5. Lin H,
    6. Wang CJ,
    7. Sun LM, et al.

    Pretreatment carcino embryonic antigen level is a risk factor for para-aortic lymph node recurrence in addition to squamous cell carcinoma antigen following definitive concurrent chemoradiotherapy for squamous cell carcinoma of the uterine cervix. Radiat Oncol 2012;7:13.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Kang S,
    3. Nam BH,
    4. Park JY,
    5. Seo SS,
    6. Ryu SY,
    7. Kim JW, et al.

    Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients withlocally advanced cervical cancer: a Korean gynecologic oncology group study. J Clin Oncol 2012;30:2369–2374.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    2. Nakamura K,
    3. Joja I,
    4. Nagasaka T,
    5. Fukushima C,
    6. Kusumoto T,
    7. Seki N, et al.

    The mean apparent diffusion coefficient value (ADCmean) on primary cervical cancer is a predictive marker fordisease recurrence. Gynecol Oncol 2012;127:478–483.

    OpenUrlPubMed
13. 13.↵
    2. Tang J,
    3. Tang Y,
    4. Yang J,
    5. Huang S.

    Chemoradiation and adjuvant chemotherapy in advanced cervical adenocarcinoma. Gynecol Oncol 2012;125:297–302.

    OpenUrlPubMed
14. 14.
    2. Leath CA 3rd.,
    3. Straughn JM Jr..

    Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol 2013;129:251–257.

    OpenUrlCrossRefPubMed
15. 15.
    2. Pectasides D,
    3. Kamposioras K,
    4. Papaxoinis G,
    5. Pectasides E.

    Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 2008;34:603–613.

    OpenUrlCrossRefPubMedWeb of Science
16. 16.↵
    2. Kitagawa R,
    3. Katsumata N,
    4. Shibata T,
    5. Nakanishi T,
    6. Nishimura S,
    7. Ushijima K, et al.

    A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG 0505). J Clin Oncol 2012;30:328.

    OpenUrl
17. 17.↵
    2. Phippen NT,
    3. Leath CA 3rd.,
    4. Miller CR,
    5. Lowery WJ,
    6. Havrilesky LJ,
    7. Barnett JC.

    Are supportive care-based treatment strategies preferable to standard chemotherapy in recurrent cervical cancer? Gynecol Oncol 2013;130:317–322.

    OpenUrlCrossRefPubMed
18. 18.↵
    2. Choi CH,
    3. Lee YY,
    4. Kim MK,
    5. Kim TJ,
    6. Lee JW,
    7. Nam HR, et al.

    A matched-case comparison to explore the role of consolidation chemotherapy after concurrent chemoradiationin cervical cancer. Int J Radiat Oncol Biol Phys 2011;81:1252–1257.

    OpenUrlPubMed
19. 19.
    2. Singh RB,
    3. Chander S,
    4. Mohanti BK,
    5. Pathy S,
    6. Kumar S,
    7. Bhatla N, et al.

    Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study. Gynecol Oncol 2013;129:124–128.

    OpenUrl
20. 20.↵
    2. Abe A,
    3. Furumoto H,
    4. Nishimura M,
    5. Irahara M,
    6. Ikushima H.

    Adjuvant chemotherapy following concurrent chemoradiotherapy for uterine cervical cancer with lymphadenopathy. Oncol Lett 2012;3:571–576.

    OpenUrlPubMed